Diminished sexual desire has been reported by 30 to 50 percent of women who undergo surgical menopause (menopause induced by the surgical removal of both ovaries), according to background information in the article. In one form of female sexual dysfunction, hypoactive sexual desire disorder, a chronic absence of desire for sexual activity results in personal distress. When the ovaries are removed (oophorectomy), blood levels of sex hormones, including testosterone, drop. Although some women see improvements in sexual functioning with estrogen therapy alone, previous studies suggest that the combination of estrogen and testosterone is more effective in preserving sexual desire.
Glenn D. Braunstein, M.D., of Cedars-Sinai Medical Center, Los Angeles, and colleagues conducted a 24-week, randomized, double blind, multicenter clinical trial in women who developed distressful low sexual desire after surgical menopause and were receiving oral estrogen therapy. The 447 women (aged 24 to 70 years) were randomized to receive placebo or testosterone patches twice weekly in one of three progressively higher doses. Testosterone levels were checked at baseline, 12 and 24 weeks. Changes in sexual desire and frequency of satisfying sexual activity were determined on the basis of a woman's reports on standardized questionnaire and sexual function activity log.
The researchers found that compared with women receiving placebo, women receiving the middle dosage (300 micrograms per day) had greater increases from baseline in questionnaire scores for sexual desire (67 percent increase over baseline compared w
'"/>
Contact: Kelli Hanley
310-423-3674
JAMA and Archives Journals
25-Jul-2005